SNYSanofiInvite-only sign-up
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Plasma Cell Myeloma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 70 (planned)
- Started
- Apr 5, 2023
- Main results expected
- Nov 30, 2028
- Fully finished
- Nov 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with treatment-emergent adverse events
Measured over: Baseline to 42 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05669989 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC